Retinnovate 2025: Equipping Retinal Disease Innovators for Market Success
| November 13th – 14th
|
Overview: We’re excited to share that Paul Ryb, Managing Director at Outcome Capital, will be speaking at Retinnovate 2025: Equipping Retinal Disease Innovators for Market Success, taking place November 13–14 at Riddell Hall, Queen’s University Belfast.Paul will present on the UK ophthalmic innovation landscape, focusing on the critical gap between early-stage breakthroughs and the funding pathways required to bring them to market. Drawing from Outcome Capital’s deep sector knowledge, he’ll address how innovators can bridge the space between grant funding and the capital needed to achieve both patient impact and investor returns.This is an essential session for researchers, founders, and investors working at the intersection of eye health and innovation commercialization. Learn more and register: https://www.flowcoevents.com/retinnovate #Retinnovate2025 #Ophthalmology #MedTech #LifeSciences #OutcomeCapital #HealthcareInnovation #VentureFunding #StartupGrowth #InvestmentBanking #RetinalDisease #EyeHealth #UKInnovation #TechTransfer |
News
A Panic Letter and the Quiet Reset of American Biotech
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read MoreResources
Outcome Capital Life Science Market Pulse, October 2025
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
